SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive mucoadhesion data for its intranasal Naloxone program, sparking excitement about its potential as a multi-day runner. Community discussions revolve around the significance of the manufacturing milestone and superior data, while some traders are wary of potential dilution given the company's history and low float. The stock is also gaining attention within the context of other low-float Israeli stocks experiencing significant moves.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the revival of OG memes on the Solana blockchain. Community members emphasize consistent engagement and building a strong culture, expressing conviction that $RAGE represents more than just a coin. Discussions highlight the importance of community over charts, with members actively working towards broader recognition and adoption.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the quantum computing sector garners attention, with discussions focusing on its superconducting QPU systems and potential for scalability compared to other quantum computing approaches. Community members debate the company's valuation relative to its revenue and the competitive landscape, while also discussing potential catalysts and trading strategies involving options. Some are optimistic about Rigetti's technology and long-term potential, while others express skepticism, citing concerns about profitability and competition from larger companies.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about a potential acquisition of Warner Bros. Discovery, with many debating whether the deal would be beneficial. Community discussions revolve around potential price targets and technical analysis, while some express concerns about the company's recent performance and programming decisions. The possibility of a bidding war with other major players like Comcast and Paramount Skydance is also fueling the conversation.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending amid speculation and excitement around the robotics sector, driven by potential government support and company-specific developments like overnight trading highs and high trading volumes. Community members are actively discussing potential short squeezes and comparing SERV to other robotics plays, anticipating further gains and focusing on the company's growth prospects with its DoorDash partnership. Some see a buying opportunity, while others are wary, pointing to past volatility and dilution.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders discuss its potential for institutional adoption and retail activity, specifically meme coins. Community members are analyzing entry points and debating its ability to outperform other cryptos, while some express concern over recent price drops. Bullish sentiment revolves around potential rallies and strong community support.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending due to its recent earnings report, which showed record revenue and profit, sparking discussions about its undervaluation relative to competitors like HOOD. The community is highlighting the company's strong growth in global client assets and its potential for significant price appreciation, drawing comparisons to HOOD's earlier run-up.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending following the release of its Q3 earnings, which beat analyst expectations and showed profitability. The community is actively discussing the company's growth, partnerships, and potential for a continued uptrend, while also debating its valuation relative to peers and the impact of short positions.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending amid mixed sentiment following recent trial setbacks and shareholder lawsuits, though analysts see potential upside and key readouts are expected in the coming quarters. Community members are weighing the risks against the potential for a buyout, drawing comparisons to other biotech successes, and closely watching the upcoming FDA meeting for clarity. Discussions also focus on technical analyses, potential market size, and institutional investment activity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to positive Phase 3 HOPE-3 trial results for their DMD treatment, deramiocel, leading to significant community excitement and a potential short squeeze. The community is focused on the implications of the data, potential FDA approval, and the possibility of a buyout, while also targeting short-sellers. With strong results in both skeletal and cardiac function, CAPR is seen as a promising player in the DMD treatment landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...

Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup

Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...

Biomea Fusion FY2025 EPS Estimate Lowered by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lowered their FY2025 EPS estimates for Biomea Fusion in a research note issued on Wednesday, November 5th. HC Wainwright analyst J...

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Moderate Buy" by Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat.com reports. One...

Biomea Fusion (NASDAQ:BMEA) Given New $12.00 Price Target at D. Boral Capital

D. Boral Capital dropped their price target on shares of Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public offering of its common stock and warrants.&nbsp;The stock closed up 10.3% at $2.9 on Tuesday but dropped 24.8% to $2.18 in after-hours trading.The offer includes shares, pre-funded warrants in place of shares to certain investors and accompanying warrants for the purchase of shares.Biomea said it will also give the underwriters a 30-day option to buy up to 15% more shares and pre-funded warrants. Jefferies is the sole book running manager.The offering is being made under a shelf registration and is expected to close on or around June 20, subject to customary closing conditions.&nbsp;Biomea said the completion, size, and terms of the offering are subject to market conditions and are not guaranteed.The offering comes just days after Biomea Fusion reported updated data from its Phase I Covalent 103 trial of BMF-500 in relapsed or refractory acute leukemia.&nbsp;The study, presented at the European Hematology Association Congress, showed early signs of clinical benefit in heavily pretreated patients with FLT3 mutations.&nbsp;The company said it plans to conclude internal development of BMF-500 in oncology and is exploring strategic partnerships to advance the program.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said the raise could bring in around $30 million and&nbsp;added that while the added dilution might pressure the stock short-term, the reduced risk could unlock further upside, predicting a return above $3 in the coming weeks.&nbsp;<stembedurl>https://stocktwits.com/hashbridges/message/618219066</stembedurl>Another user expressed disappointment at the timing of the offering, saying they anticipated it at a higher price and would now hold the stock through year-end.<stembedurl>https://stocktwits.com/aquira/message/618214880</stembedurl>The stock has declined 21.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients. 

Equity

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

Shares of Biomea Fusion attracted significant retail attention on Tuesday after H.C. Wainwright reduced its price target for the stock to $18 from $40, while maintaining a ‘Buy’ rating.&nbsp;The&nbsp;reduction followed the company’s first-quarter earnings report, where Biomea unveiled a strategic shift to focus on its core diabetes and obesity programs.&nbsp;As part of its strategy, Biomea has implemented a cost-reduction initiative, which includes a workforce reduction of nearly 35% to reduce overall operating expenses and extend its cash runway into Q4 2025.The firm also removed type 1 diabetes from its projections and pushed the launch of icovamenib for type 2 diabetes to 2031 from the previously anticipated 2029.Biomea’s stock price declined by 16.5%, closing at $1.67 on May 6, 2025. However, it rebounded slightly in after-hours trading, increasing by 1.74% to $1.70.Retail sentiment surged on Stocktwits, where sentiment was ‘bearish’ views amid a 1,400% uptick in message volume.&nbsp;The sentiment seemed to reflect speculation about the company’s next moves and the market’s potential reactions.One user questioned the company’s decision to delay share dilution when the stock was priced at $4 earlier this year, suggesting that the current price of $1.60 might not align with Biomea’s broader plans, hinting that something was amiss.&nbsp;<stembedurl>https://stocktwits.com/NGEA/message/613687181</stembedurl>Meanwhile, another user speculated that Biomea's recent actions could indicate a “short trap” and accumulation of shares ahead of potential positive news.&nbsp;The user pointed out that despite concerns of running out of cash, Biomea had not raised funds through share sales but instead reduced its workforce to stretch its runway.<stembedurl>https://stocktwits.com/NGEA/message/613678729</stembedurl>In its Q1 update, interim CEO Mick Hitchcock highlighted the company’s efforts to prioritize high-value opportunities, extend its cash runway, and maintain its focus on icovamenib and BMF-650.&nbsp;Biomea also reported a Q1 net loss of $29.3 million, with cash reserves of $36.2 million, expected to fund operations until Q4 2025.Shares of Biomea have fallen 54.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves

Biomea Fusion is realigning its focus on diabetes and obesity programs, cutting 35% of its workforce and consolidating operations to reduce costs. 

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate

FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, allowing the ongoing studies to resume.
read more...

IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.23	--	--	N/A
Q3 '25	-$0.26	-$0.27	-5.37%	MISSED
Q2 '25	-$0.53	-$0.51	3.92%	BEAT
Q1 '25	-$0.61	-$0.80	-30.72%	MISSED
Q4 '24	-$0.92	-$0.81	11.60%	BEAT

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BMEA News

BMEABiomea Fusion Inc